VINCOV-19 India’s first antidote for COVID-19 awaits market authorisation

by Gyanvitaranam

The Centre for Cellular and Molecular Biology (CCMB) has announced the success of COVID-19 antidote, VINCOV-19, in phase 2 clinical trials. The scientists at CCMB collaborated with Central University, Hyderabad and VINS Bioproducts Limited, a leading immunological company based in Hyderabad, for the synthesis of Coronavirus neutralizing antibodies.

It is claimed that these antibodies are more efficient in treating patients in comparison to the established COVID-19 plasma therapy. Scientists at CCMB inoculated an equine (a horse or other member of the horse family) with chemically inactivated SARS-CoV-2, the virus that causes COVID-19. The hyper immunised equine generated antibodies which were fractionated to extract F(ab’)2 fragments, having a high potency to neutralise five different variants of COVID-19 virus, including the Delta variant.

Since the outbreak of the pandemic, several vaccines have been released on the market and some of them have proved to....

Want to keep reading? Subscribe now

Already a subscriber? Sign in here

Subscribe Now

Back Issues